$30.95
2.157.47%
At Close: -
$30.95
00.00%
After Hours: 4:52 PM EDT
15 minutes delayed
Comments
Loading...
Spyre Therapeutics
SYRENASDAQ
Spyre Therapeutics (NASDAQ:SYRE) Stock, Analyst Ratings, Price Targets, Forecasts
Spyre Therapeutics Inc has a consensus price target of $43.17 based on the ratings of 8 analysts. The high is $54 issued by Stifel on March 26, 2024. The low is $31 issued by Jefferies on December 11, 2023. The 3 most-recent analyst ratings were released by Wells Fargo, BTIG, and Baird on May 13, 2024, May 10, 2024, and May 2, 2024, respectively. With an average price target of $43.33 between Wells Fargo, BTIG, and Baird, there's an implied 40.01% upside for Spyre Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Wells Fargo
BTIG
Baird
Stifel
Guggenheim
1calculated from analyst ratings
Analyst Ratings for Spyre Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/16/2024 | Buy Now | — | Evercore ISI Group | Umer Raffat | — | Initiates | → Outperform | Get Alert |
| 05/13/2024 | Buy Now | 29.24% | Wells Fargo | Yanan Zhu | $35 → $40 | Maintains | Overweight | Get Alert |
| 05/10/2024 | Buy Now | 29.24% | BTIG | Julian Harrison | $32 → $40 | Maintains | Buy | Get Alert |
| 05/02/2024 | Buy Now | 61.55% | Baird | Colleen Kusy | → $50 | Initiates | → Outperform | Get Alert |
| 03/26/2024 | Buy Now | 74.47% | Stifel | Alex Thompson | $36 → $54 | Reiterates | Buy → Buy | Get Alert |
| 03/01/2024 | Buy Now | 13.09% | Wells Fargo | Yanan Zhu | $12 → $35 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 12/20/2023 | Buy Now | 3.39% | BTIG | Julian Harrison | → $32 | Initiates | → Buy | Get Alert |
| 12/18/2023 | Buy Now | -12.76% | Stifel | Alex Thompson | $23 → $27 | Maintains | Buy | Get Alert |
| 12/11/2023 | Buy Now | 42.16% | Guggenheim | — | → $44 | Initiates | → Buy | Get Alert |
| 12/11/2023 | Buy Now | 0.16% | Jefferies | Akash Tewari | → $31 | Initiates | → Buy | Get Alert |
| 11/29/2023 | Buy Now | — | TD Cowen | Tyler Van Buren | — | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for Spyre Therapeutics (SYRE) stock?
The latest price target for Spyre Therapeutics (NASDAQ:SYRE) was reported by Evercore ISI Group on July 16, 2024. The analyst firm set a price target for $0.00 expecting SYRE to fall to within 12 months (a possible -100.00% downside). 11 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Spyre Therapeutics (SYRE)?
The latest analyst rating for Spyre Therapeutics (NASDAQ:SYRE) was provided by Evercore ISI Group, and Spyre Therapeutics initiated their outperform rating.
When was the last upgrade for Spyre Therapeutics (SYRE)?
The last upgrade for Spyre Therapeutics Inc happened on March 1, 2024 when Wells Fargo raised their price target to $35. Wells Fargo previously had an equal-weight for Spyre Therapeutics Inc.
When was the last downgrade for Spyre Therapeutics (SYRE)?
There is no last downgrade for Spyre Therapeutics.
When is the next analyst rating going to be posted or updated for Spyre Therapeutics (SYRE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Spyre Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Spyre Therapeutics was filed on July 16, 2024 so you should expect the next rating to be made available sometime around July 16, 2025.
Is the Analyst Rating Spyre Therapeutics (SYRE) correct?
While ratings are subjective and will change, the latest Spyre Therapeutics (SYRE) rating was a initiated with a price target of $0.00 to $0.00. The current price Spyre Therapeutics (SYRE) is trading at is $30.95, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.